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SUMMARY
Introduction Chronic lymphocytic leukemia (CLL) has an extremely variable clinical course. Biological 
reasons for that wide variation in clinical course and survival rates in CLL patients are not fully understood.
Objective The aim of the study was to evaluate the value of spontaneous apoptosis of CLL cells in vitro 
determined at presentation of disease, in prediction of treatment requirements and evolution of the CLL.
Methods Malignant B cells were isolated from the whole blood of 30 newly diagnosed CLL patients and 
cultured for 24 hours in RPMI-1640 medium supplemented with 10% of serum obtained from the same 
CLL patient. Cells were later fixed and processed for embedding in Epon, or cell smears were prepared 
and stained with TUNEL technique.
Results Ten-year follow-up revealed that patients with lower percentage of cells in apoptosis at presen-
tation of disease had significant longer time treatment initiation (log rank test p<0.05). On the contrary, 
apoptosis of CLL cells was not shown to have significant impact on survival of patients (Kaplan Meier 
log rank test p>0.05).
Conclusion The results of this study emphasize the importance of apoptosis of CLL cells at the time of 
the initial diagnosis in pathobiology of this disease.
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INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the 
most frequent type of leukemia in the Western 
world [1] and has an extremely variable clinical 
course with survival ranging from few months 
to decades [1, 2]. Biological reasons for wide 
variation in clinical course and survival rates of 
CLL patients are not fully understood; therefore, 
the search for prognostic factors contributing to 
proper management of patients with CLL has 
become important in the last two decades [2].
Up to now, a certain number of clinical and 
biological markers of prognostic relevance has 
been identified [3]. There are three traditional 
clinical prognostic factors: the clinical stage 
according to either Rai or Binet [4], the lym-
phocyte doubling time [5, 6] and bone mar-
row infiltration pattern [7, 8]. Two of the most 
reliable molecular prognostic markers are the 
immunoglobulin heavy chain variable (IGHV) 
gene mutational status and fluorescence in situ 
hybridization (FISH) detection of prognosti-
cally relevant genomic aberrations (e.g. 11q-, 
13q-, +12 and 17p-) [9]. In addition to these 
markers, a myriad of additional biomarkers 
have been postulated as potential prognostic 
factors in CLL, proteins (e.g. CD38, ZAP70, 
TCL1), the RNA (e.g. LPL, CLLU1, micro-
RNAs) and the genomic (e.g. TP53, NO, TCH1, 
SF3B1 and BIRC3 mutations) [9]. Recently, 
two new biological markers, the expression of 
CD38 antigen and ZAP-70 have shown inde-
pendent significance in prediction of prognosis 
in CLL patients [10]; although these prognostic 
factors are used currently in practice, they are 
time-consuming and require standardization 
of laboratory protocol [11]. New prognostic 
factors are still needed.
The neoplastic population of cells in CLL is 
characterized by a very low proliferative rate. 
The accumulation of these cells in G0 phase of 
the cell cycle [12, 13, 14] cannot be explained 
only by cell proliferation but seems to be the 
result of prolonged survival of these cells as 
well [15, 16]. Despite of their long survival 
in vivo due to an increased capacity to resist 
normal apoptotic signals, in vitro CLL cells die 
rapidly by apoptosis [12]. These in vitro find-
ings suggest that some factors (humoral or cel-
lular), necessary for the survival of these cells, 
are missing from the culture media [12]. The 
results of recent study [13], suggested a rela-
tionship between higher in vitro spontaneous 
apoptosis before treatment in advanced-stage 
patients with poor outcome.
OBJECTIVE
The aim of this study was to evaluate whether 
spontaneous apoptosis of CLL cells in vitro      
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determined at presentation of disease could predict the 
evolution of CLL.
METHODS
Thirty previously untreated patients with CLL, referred 
to the Institute of Hematology, Clinical Center of Serbia, 
University of Belgrade in 2000, were enrolled in this pro-
spective study. They were followed up for 10 years, until 
2010. This study was approved by the Ethics Committee 
of Medical Faculty Belgrade and the Institutional Review 
Board. The informed consent was obtained from all pa-
tients. Peripheral blood samples were obtained from CLL 
patients at the time of diagnosis, before the initiation of 
any treatment, and during regular diagnostic procedure. 
Diagnosis and clinical staging of CLL were based on the 
National Cancer Institute criteria (NCI) [4]. Bone mar-
row biopsies were available in 23 CLL patients. Evalua-
tion of spontaneous apoptosis in CLL cells in vitro was 
performed at the Institute of Histology and Embryology, 
Medical Faculty of Belgrade. Patients were followed-up 
and treated according to the standard clinical protocol of 
the Institute of Hematology at the time of diagnosis (no 
Fludarabine based treatment). Data from medical docu-
mentation were reviewed in order to determine the time 
of the initiation of CLL treatment for every patient and 
other relevant clinical data.
Peripheral blood was collected using preservative-free 
heparin as the anticoagulant. Serum was withdrawn after 
sedimentation of coagulated blood samples obtained from 
all patients. Malignant B lymphocytes were isolated us-
ing sedimentation of the blood cells on Ficoll gradients 
(Lymphoprep®). Cells (5×106/ml) were cultured in RPMI-
1640 medium (Sigma®) supplemented with 10% of serum 
obtained from the same CLL patient (autologous serum, 
AS) and incubated for 24 hours, 37o C, with 5% CO2 and 
98% humidity.
Immediately after separation (0 h) and after incuba-
tion (24 h), cells were fixed and processed for embedding 
in Epon (Agar Scientific®). One micrometer thick sections 
were stained with toluidine blue for light microscopy, where 
apoptotic cells were identified by the presence of nuclear 
condensation and/or fragmentation, based on previously 
defined morphological criteria [17-20]. Apoptotic cells were 
counted in 5 randomly chosen high power fields (100x oil 
immersion objective), and was expressed as a percentage of 
a total number of counted cells (apoptotic index, AI) (Figure 
1). Thin sections were mounted on copper grids and stained 
with uranyl acetate and lead citrate and further examined 
by electron microscope (Morgagni 268D).
To identify fragmented DNA, a TdT-mediated dUTP 
nick-end labeling (TUNEL) assay was performed on CLL 
cell smears. After fixation in 4% paraformaldehyde and 
permeabilization with 0.2% Triton X-100, cells were treat-
ed with 3% bovine serum albumin and TUNEL reaction 
mixture. Converter for alkaline phosphatase was applied, 
and Fast red was used to visualize the signal for light mi-
croscopy. TUNEL positivity was seen within the apoptotic 
CLL cell nuclei as granular red nuclear staining (Figure 1). 
CLL cells were counted in 10 random high-power fields 
(x400) on each cell slide and the index of apoptosis was 
determined and expressed as percentage.
Statistics
All data were analyzed by the methods of descriptive para-
metric (mean, standard deviation and standard error, t-
test and ANOVA) and nonparametric statistics (median, 
Chi square, Mann Whitney U test, Kruskall Wallis test) 
and also by survival analysis according to Kaplan Meier 
method together with Cox multivariate regression mod-
el and log rank test. All statistical tests were considered 
significant at level of at least p<0.05. Statistical analysis 
was performed using licensed STATISTICA 8.0 software 
(StatSoft Inc, Tulsa, USA).
RESULTS
Patient characteristics
Our cohort of patients with CLL consisted of 18 men 
(66.7%) and 12 women (43.3%). At the time of diagnosis, 
the mean age of patients was 61.5±8.7 years, median 62.5 
years, and ranged from 42 to 81 years. At presentation of 
disease, the majority of patients (80%, 24 patients) was in 
the early phase of disease defined as low Rai stages (clinical 
stage 0 in 8 patients, I in 9 patients, and II in 7 evaluated   
Figure 1. Freshly isolated CLL cells (A, C, E) and incubated for 24 hours 
(B, D, F). CLL cells on 1 μm thin section stained with toluidine blue (A, 
B), and viewed by electron microscopy (C, D). Number of CLL cells 
shows typical morphological features of apoptosis like condensation 
of cytoplasm and chromatin, with the formation of coarse granular 
chromatin masses after 24 hours incubation (B, D). TUNEL method 
performed on CLL cell smears, counterstained with Mayer hematoxylin 
(E, F). The presence of TUNEL-positive cells (nuclei stained red) is more 
frequent among cells incubated for 24 hours (F).  
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patients), while 6 patients (20%) had advanced Rai stages 
(3 patients had stage III and 3 patients had stage IV dis-
ease). The difference in absolute lymphocyte count be-
tween early (35.3±56.4×109/L) and advanced stage CLL 
(56.9±59.7×109/L) was noted, but this difference was not 
statistically significant. Bone marrow biopsy was per-
formed in 26 patients, but quality specimen was obtained 
in 23 patients. Diffuse infiltration pattern was found in 6 
patients. Lymphocyte doubling time (LDT) was defined 
according to well-defined criteria and LDT <12 months 
was observed in 12 patients (42.9%), and LDT>12 months 
was noted in 16 patients (57.1%) while there were no ac-
curate medical records for 2 patients.
In ten-year follow up, two patients remained in indolent 
stage of disease and did not require  any treatment, while 
the rest of patients required therapy either immediately 
after diagnosis and staging of CLL or up to 8 years of ob-
servation (in 5 of 6 patients with diffuse pattern of bone 
marrow, infiltration therapy was initiated in the first year 
of disease).
Detection of apoptosis in CLL cells at presentation 
of disease
Freshly isolated CLL cells from peripheral blood (0h) 
showed low number of apoptotic cells (AI0h 3.8±1.7%). 
Apoptotic index of CLL cells cultured for 24 hours with au-
tologous serum (AI24h 17.7±9.7%) was significantly higher 
(p<0.05) than in freshly isolated cells. No significant dif-
ference in the percentage of spontaneous apoptosis of CLL 
cells was noticed when apoptosis was measured using 
TUNEL technique or toluidine blue stained sections (AI24h 
17.7±9.7% and 17.1±9.1%, respectively). Data obtained 
using TUNEL technique was used further in the text.
There was no significant difference in apoptotic index 
(AI0h and AI24h) between different Rai stages (ANOVA 
p>0.05), although somewhat higher values in advanced 
stages of CLL were found. In addition, difference of the 
increment of apoptosis defined as a rise in percentage from 
0h to 24h (∆AI) was tested among these groups of patients, 
but no significant difference was found. Higher values of 
∆AI in advanced Rai stages was also noticed (Graph 1).
Considering that there is a biological difference in CLL 
behavior between early and advanced Rai stages, we also 
performed the same analysis by grouping the patients with 
early CLL phase (Rai 0, I, II) and advanced CLL phase (Rai 
III and IV). Apoptotic index, AI0h was significantly higher 
(5.8±0.4%) in the advanced stage patients (ASP) compared 
to the early stage patients (ESP) (3.1±1.4%) (p<0.05). Dif-
ference in the AI24h between these two groups of patients 
was also observed (AI24h in ASP was 27.1±7.1%; and in 
ESP was 15.2±8.7%), but this difference was not proven 
to be significant due to high variability of data. Early stage 
CLL patients had lower increase in ∆AI (12.2±8.9%) than 
late stage patients (21.2±7.2%) but this difference was not 
significant (Graph 2).
Apoptotic index of CLL cells obtained from the patients 
with diffuse infiltration of bone marrow did not vary sig-
nificantly from that determined in patients with other 
types of infiltration, either in freshly isolated CLL cells 
(AI0h 3.6±1.6%, 3.9±1.8% respectively), or in cells incu-
bated for 24h (AI24h 16.1±2.6% and 16.9±9.0%).
In patients with short doubling time, LDT<12 months, 
AI0h was higher (4.0±1.9%) than in the cells obtained from 
patients with longer LDT (3.4±1.5%) (Mann Whitney U 
test, p<0.10). AI24h was also different between respective 
groups of patients with LDT <12 months (19.0±10.5%) 
and LDT>12 months (14.3±6.3), but this difference was 
not significant (p>0.05) (Graph 3).
Time to treatment initiation (TTI)
During 10-year follow up of our CLL patients, 22 patients 
received therapy at certain time, 5 patients did not receive 
therapy at all and 3 patients were lost in the follow up. 
Early stage CLL patients had significantly longer TTI time 
(median was 4 years) compared to advanced stage patients 
(median less than 1 year; log rank test p<0.01). Patients 
with LDT >12 months had also significantly longer TTI 
than those with LDT <12 months (TTI50% is 5 versus 1 
year; log rank test p<0.05).
It was observed that patients with lower percentage of 
AI0h (<5%) required therapy later (median 5 years), while 
those with higher AI0h (>5%) demanded therapy earlier 
(median 1 year). By evaluating TTI time according to this 
threshold, it was found that patients with lower AI0h had 
significantly longer TTI time (log rank test p<0.05; Graph 
4). Although patients with ∆AI at threshold less than 15% 
had longer TTI period (median 4 years) than those with 
∆AI >15% (median was 2 years), rise in apoptosis had no 
significant influence on TTI (Kaplan Meier log rank test 
p>0.05).
Ten-year survival period
Early stage CLL patients had, as expected, significantly 
longer overall survival (median OS was 10 years) than ad-
vanced stage patients (median was 2 years) (Kaplan Meier 
log rank test p<0.01). Patients with LDT>12 months had 
longer survival than those with shorter LDT, <12 months 
(OS50% 10 y vs. 5 years, Kaplan Meier log rank test p<0.10).
CLL patients with AI0h<5% had longer survival (OS50% 
10 years), while those with AI0h>5% had shorter (OS50% 
7 year), but AI0h at this threshold was not shown to have 
significant impact on survival of patients (Kaplan Meier 
log rank test p>0.05). Cox multivariate analysis model 
with lymphocyte doubling time (LDT), AI0h and increase 
in percentage of apoptosis during 24h (∆AI) revealed that 
AI0h behaved as an independent factor for time to treat-
ment initiation, TTI (p<0.05). When distinction of stage 
(early/advanced) was added in Cox multivariate regres-
sion model, only clinical stage of disease behaved as an 
independent factor (variable) for both time to treatment 
initiation (p<0.05) and survival (p<0.05), while apoptosis 
and LDT were not independent variables any more.     
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DISCUSSION
A large variety of clinical manifestations and variable sur-
vival rates are well documented in CLL patients [2, 3]. In 
our study, groups of patients with the advanced-stage and 
patients with the early-stage disease at the enrollment were 
in concordance with recently published epidemiological 
estimations describing that in the first year of CLL, 20% 
of patients would be in the advanced stage [20]. Other 
traditional adverse prognostic factors like diffuse infiltra-
tion of bone marrow and LDT less than 12 months were 
present in minority of patients. Similar observations were 
found in other studies [13, 21].
The fact that CLL cells die by the spontaneous apoptosis 
in cell cultures supplemented with fetal calf serum is well 
documented [22]. We tested whether autologous serum 
contains some factors which may alter the survival time of 
CLL cells in vitro. Autologous serum failed to protect CLL 
cells from spontaneous apoptosis. Previously published 
data are in concordance with our results [21]. We have 
observed substantial variation in the level of spontane-
ous apoptosis of CLL cells in different patients. Variations 
in the level of spontaneous apoptosis in CLL was noticed 
before and is believed to be the result of cell-intrinsic dif-
ferences in CLL cells susceptibility to apoptosis, or occur 
due to variable levels of protective components in the 
serum of different patients [22]. Activation of the PI3K/
Akt cytoprotective-signaling pathway by plasma may con-
tribute to its anti-apoptotic action [23]. Since autologous 
serum failed to prevent apoptosis in vitro, variation in the 
level of spontaneous apoptosis of CLL cells seen in differ-
ent patients is possibly related to differential expression of 
apoptosis regulating proteins [15] rather than to variable 
levels of protective components in the serum of different 
patients. Our data confirm a model in which the longev-
ity of CLL cells is determined by the interplay between 
the intrinsic disease-related genetic changes and survival 
signaling by environmental factors [15].
In our study, higher percentage of apoptosis was no-
ticed to be present in the advanced-staged patients and 
patients with short doubling time (LDT<12 mo). It has 
Graph 4. Time to treatment initiation (TTI) in patients with Apoptotic 
index (AI) of freshly isolated CLL cells (AI0h) higher than 5% (>5%) and 
lower than 5% (<5%)
Graph 2. Differences in Apoptotic index (AI) of freshly isolated CLL 
cells (AI0h), after 24h of incubation with autologous serum (AI24h), and 
rise in percentage of apoptosis from 0h to 24h (∆AI) between early-
staged and advanced-staged CLL patients
The data are mean ± SD values.
* p<0.05
Graph 1. Apoptotic index (AI) of freshly isolated CLL cells (AI0h), after 
24h of incubation with autologous serum (AI24h), and difference in AI 
(∆AI), defined as rise in percentage of apoptosis from 0h to 24h, in 
different Rai groups of patients
The data are mean ± SD values.
p>0.05
Graph 3. Differences in Apoptotic index (AI) of freshly isolated CLL 
cells (AI0h), after 24h of incubation with autologous serum (AI24h), and 
difference in AI (∆AI), between patients with lymphocyte doubling 
time less than 12 months (LDT<12 m), and patients with lymphocyte 
doubling time more than 12 months (LDT>12 m). 
The data are mean ± SD values.
p>0.05  
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been published recently that patients showed significantly 
better in vitro response to purine analogues when they 
were in the initial stages of the disease, with low beta(2) 
microglobulin serum level, with long LDT, with few cells 
expressing CD38, with normal karyotype or no p53 dele-
tion, whereas there was no correspondence with ZAP-70 
expression [24]. It has been also published before that the 
expression of apoptosis regulating protein Mcl-1 signifi-
cantly correlates with LDT and with the stage of disease 
[25]. Bone marrow infiltration was the only classical prog-
nostic factor examined that was not found to be related 
to apoptosis of leukemic cells. There are no previously 
published data regarding correlation between spontane-
ous apoptosis of CLL cells and bone marrow infiltration.
Higher percentage of spontaneous apoptosis in ad-
vanced-stage patients and higher proliferation of leukemic 
cells and poor outcome was suggested by Sieklucka M et 
al. [13]. Contradictory data on the relationship between 
proliferative markers and disease progression in CLL were 
published [21]. Increased proliferation, measured by Ki67 
and sCD23 [26, 27] was described in CLL cells of patients 
with the advanced-stage disease. Vrhovac et al. [28], on the 
contrary, reported a high expression of cell cycle inhibi-
tor p27 in progressive CLL disease, suggesting that CLL 
cells expressing low p27 levels could be characterized by 
higher levels of apoptosis. Ricciardy et al. [19] found that 
CLL cells in patients with progressive disease had more 
quiescent status and reduced susceptibility to apoptosis. 
The subdivision of CLL, to progressive and stable disease, 
does not always match the clinical staging, and indeed the 
authors noted that four patients considered having pro-
gressive disease have been staged as Rai 0 or I [21]. The 
difference in grouping of samples might be a reason for 
different results obtained in the study of Ricciardy et al. 
[21] compared to our study and the study of Sieklucka et 
al. [13].
During 10-year follow up of our cohort of CLL patients, 
it was noticed, as expected, that patients with negative 
prognostic factors like advanced stage disease and LDT 
less than 12 months, required therapy earlier, and had 
shorter overall survival time. It was also noted that patients 
with higher percentage of spontaneous apoptosis of CLL 
cell also required therapy earlier. Apoptotic index of fresh-
ly isolated cells was shown to have significant influence on 
TTI in our study, but did not have significant influence 
on survival of patients. Apoptosis of freshly isolated cells 
behaved as an independent factor for TTI period when 
other variables, like LDT and ∆AI, were included in Cox 
multivariate regression model. But, with addition of stage 
of disease (early/advanced) to Cox multivariate analysis 
model, the apoptosis was not an independent factor any 
more. The main independent prognostic factor in CLL is 
stage of the disease.
Our results after ten-year follow up of CLL patients are 
somehow consistent with the baseline findings when the 
patients were seen for the first time. Relationship between 
high levels of apoptosis and poor prognosis was seen both 
at the beginning and at the end of study. At the beginning 
of study, high levels of apoptosis were detected in patients 
presenting with bad prognostic factors, like advanced Rai 
stage and short LDT. At the end of this study, higher levels 
of apoptosis were found in patients with shorter therapy 
free period. Relationship between high levels of apoptosis 
and poor prognosis is thus consistent in this study. 
CONCLUSION
The results of this study draw attention to the relation of 
high levels of apoptosis among CLL cells at the time of 
the initial diagnosis and poor prognosis, emphasizing the 
importance of apoptosis in pathobiology of the chronic 
lymphocytic leukemia. 
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КРАТАК САДРЖАЈ
Увод Хро  нич  на лим  фо  цит  на ле  у  ке  ми  ја (ХЛЛ) има из  у  зет  но 
про  мен  љив кли  нич  ки ток. Би  о  ло  шки раз  ло  зи ко  ји до  во  де 
до ве  ли  ких ва  ри  ја  ци  ја у кли  нич  ком то  ку и сте  пе  ну пре  жи-
вља  ва  ња бо  ле  сни  ка са ХЛЛ ни  су пот  пу  но раз  ја  шње  ни.
Циљ ра  да Циљ сту  ди  је је био да се утвр  ди ва  жност од  ре  ђи-
ва  ња спон  та  не апоп  то  зе ХЛЛ ће  ли  ја in vi tro на презентацију 
бо  ле  сти ра  ди прог  но  зе то  ка ове бо  ле  сти и по  тре  бе за ле  че-
њем бо  ле  сни  ка са ХЛЛ.
Ме  то  де ра  да Ле  у  ке  миј  ски лим  фо  ци  ти изо  ло  ва  ни су из 
пе  ри  фер  не кр  ви 30 но  во  ди  јаг  но  сти  ко  ва  них бо  ле  сни  ка и 
ин  ку  би  ра  ни 24 ча  са у РП  МИ-1640 ме  ди  ју  му обо  га  ће  ним са 
10% се  ру  ма до  би  је  ног од истог бо  ле  сни  ка са ХЛЛ. Ће  ли  је 
су ка  сни  је фик  си  ра  не и ка  лу  пље  не у Епо  ну или су од њих 
пра  вље  ни ће  лиј  ски раз  ма  зи ко  ји су бо  је  ни TUNEL тех  ни  ком.
Ре  зул  та  ти То  ком де  се  то  го  ди  шњег пе  ри  о  да ис  пи  ти  ва  ња 
от  кри  ве  но је да су бо  ле  сни  ци с ма  њим про  цен  том апоп  то-
тич  них ће  ли  ја на пре  зен  та  ци  ји бо  ле  сти има  ли ду  жи пе  ри  од 
до за  по  чи  ња  ња те  ра  пи  је (log-rank тест, p<0,05). Апоп  то  за 
ХЛЛ ће  ли  ја, ме  ђу  тим, ни  је има  ла зна  ча  јан ути  цај на пре  жи-
вља  ва  ње бо  ле  сни  ка (Ка  план–Мајеров log-rank тест, p>0,05).
За  кљу  чак Ре  зул  та  ти ове сту  ди  је ука  зу  ју на зна  чај апоп  то  зе 
ХЛЛ ће  ли  ја у тре  нут  ку ди  јаг  но  зе бо  ле  сти у па  то  ге  не  зи хро-
нич  не лим  фо  цит  не ле  у  ке  ми  је.
Кључ  не ре  чи: апоп  то  за; хро  нич  на лим  фо  цит  на ле  у  ке  ми  ја; 
ауто  лог  ни се  рум; прог  но  за; пре  жи  вља  ва  ње
Висок проценат апоптотичних ћелија in vitro у тренутку постављања дијагнозе 
хроничне лимфоцитне леукемије указује на ранију потребу за лечењем особа 
с овом болешћу: десетогодишње испитивање
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